Oncolytics Biotech
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 26
- Market Cap
- $74.3M
- Introduction
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 48
- Registration Number
- NCT04215146
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 26
- Registration Number
- NCT04102618
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital La Paz, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
- Conditions
- Muscle-invasive Transitional Cell Carcinoma of the Bladder
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Oncolytics Biotech
- Registration Number
- NCT02723838
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 11
- Registration Number
- NCT02620423
- Locations
- 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
- Conditions
- KRAS Mutant Metastatic Colorectal Cancer
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 36
- Registration Number
- NCT01274624
- Locations
- 🇺🇸
Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸New York Presbyterian Hospital/ Weill Cornell Medical College, New York, New York, United States
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
- Conditions
- Carcinoma, Squamous Cell of the Head and Neck
- Interventions
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 167
- Registration Number
- NCT01166542
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 34
- Registration Number
- NCT00998322
- Locations
- 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
🇺🇸Montefiore Medical Center, New York, New York, United States
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
- Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 32
- Registration Number
- NCT00998192
- Locations
- 🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 14
- Registration Number
- NCT00984464
- Locations
- 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
- Conditions
- Carcinoma, Non-small Cell Lung
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 37
- Registration Number
- NCT00861627
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States